KAHR Bio

Modi'in Makabim-Re'ut, Israel · Founded 2005 · Privately Held (backing)

Developer of a cancer drug intended to activate immune responses by converting cancer camouflage into beacons for the immune system to attack. KAHR Bio is based in Modi'in Makabim-Re'ut, Israel and was founded in 2005. Its last reported valuation was $166 million in Nov 2022. It has raised $183 million.

Last reported valuation
$165.7M
Oct 2026
Priced at
—
Total raised
$183.3M
Last round
—

Who backs KAHR Bio?

19 investors
InvestorType
Korea Investment PartnersVenture capital
Innovation AuthorityOther
Peregrine VenturesVenture capital
SPRIM Global InvestmentsOther
Consensus Business GroupFund of funds
Pavilion Capital PartnersOther
DAFNA Capital ManagementHedge fund
BVF Partners—
Cancer Focus Fund—
DSC Investment—
+ 9 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

KAHR Bio investors

19 investors are on record for KAHR Bio, including Korea Investment Partners, Innovation Authority, Peregrine Ventures and SPRIM Global Investments.

Free account
More of KAHR Bio with a free account
  • ·The complete investor list: 19 names
  • ·Watch KAHR Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 19 firms already write checks for companies like KAHR Bio. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View